A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer


Byers L. A., Navarro A., Schaefer E., Johnson M., Ozguroglu M., Han J., ...Daha Fazla

CLINICAL LUNG CANCER, cilt.22, sa.6, ss.531-540, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 22 Sayı: 6
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.cllc.2021.04.005
  • Dergi Adı: CLINICAL LUNG CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.531-540
  • Anahtar Kelimeler: Checkpoint kinase 1 inhibitor, Relapsed, Refractory, Small cell lung cancer, Pharmacokinetics, Biomarker, 2ND-LINE TREATMENT, TOPOTECAN, CYCLOPHOSPHAMIDE, VINCRISTINE, CISPLATIN
  • İstanbul Üniversitesi Adresli: Evet

Özet

Patients with extensive-stage small-cell lung cancer (ED-SCLC) need improved outcomes in the relapsed/refractory setting. This phase II study evaluated the safety and efficacy of prexasertib, a checkpoint kinase 1 inhibitor, in platinum-sensitive and platinum-refractory ED-SCLC. Prexasertib demonstrated response rates of 5.2% in platinum-sensitive and 0% in platinum-refractory ED-SCLC. Prexasertib did not show prespecified efficacy as monotherapy in ED-SCLC.